News

FTSE 100 Live: Tesla Revs Up UK Energy Market Entry, GSK and S4 Capital in Spotlight

FTSE 100 Rises by 0.3% to 9,124.03 as Tesla Targets UK Energy Market and Corporate Updates Drive Moves

Written By : Bhavesh Maurya
Reviewed By : Manisha Sharma

London’s FTSE 100 confidently opened the week, advancing 0.3%, or 28.30 points, to 9,124.03, supported by gains in Diageo, Marks & Spencer, and AstraZeneca, each moving up by 1%. The uplift helped offset losses in some industrial and defence names. Let’s take a look at the FTSE 100 live today updates.

Tesla Plots UK Energy Supply Push

Electric vehicle giant Tesla has taken steps to enter Britain’s energy supply sector, applying to Ofgem for a license that would allow it to sell electricity to homes and businesses in England, Scotland, and Wales. If approved, operations could begin as soon as 2026.

The application, signed by Andrew Payne, Tesla’s European energy director, follows the company’s earlier UK electricity generation license granted in 2020. It reflects Tesla's energy supply activities in Texas and aligns its energy products with its growing solar and battery storage operations. Tesla has turned to auxiliary sources of revenue as EU EV demand has softened.

Notable Market Movers

Despite the jump in FTSE 100 prices, some blue-chip names struggled. Melrose Industries slipped to £581.6, BAE Systems fell £26.5 to £1,711, Rolls-Royce eased to £1,060, and Shell dropped £16 to £2,637.

The FTSE 250 was little changed at 21,962.75, with Marshalls and Plus500 both down around 4% after releasing half-year results.

Corporate Updates

Fabergé Sold: Gemfields has sold the luxury brand Fabergé to US investment firm SMG Capital for $50 million (£37.1 million). New owner Sergei Mosunov pledged to preserve the brand’s prestige while expanding its reach in jewelry, accessories, and timepieces. Gemfields said the sale streamlines operations and strengthens its balance sheet.

Oxford Nanopore CEO to Step Down: Co-founder Gordon Sanghera will leave his role as chief executive by the end of next year after leading the FTSE 250 biotech since 2005. The company, now valued at £2 billion, has seen its share price double since April but remains below its 2021 IPO level.

GSK Drug Advances: GSK shares rose 1% to £1,411.45 after the FDA granted priority review to gepotidacin, an oral antibiotic for gonorrhea, with a decision expected by December 2025.

Sorrell’s S4 Capital in Merger Talks: Advertising group S4 Capital, founded by Sir Martin Sorrell, confirmed preliminary merger discussions with MSQ Partners. Reports also suggest interest from US private equity firm New Mountain Capital.

Global Context

Investor sentiment was supported by Chinese inflation data for July, which showed no month-on-month decline, beating forecasts. Brent crude traded at $66.28 a barrel, while sterling held at $1.3467.

With corporate activity and global data both offering positive signals, the FTSE 100 began the week on solid ground, though traders remain cautious amid a packed economic calendar.

Join our WhatsApp Channel to get the latest news, exclusives and videos on WhatsApp

4 Best Cryptos to Invest in 2025 That Could Deliver Massive Long-Term Gains: BlockDAG, Litecoin, Stellar, & Toncoin

Cold Wallet’s Reward-Driven Model and $5.86M Presale Put It Ahead of VET’s Partnerships and ETH’s $3,700 Push!

Crypto Whales Accumlating OZAK AI—Here’s Why It Could Deliver 3000% Gains Compared to Ethereum and XRP

Ethereum (ETH) and Ripple (XRP) Technicals Show Positive Signs, But It's This Crypto's Momentum That's Shocking Everyone

Bitcoin News Today: Analysts Predict $150K by Year-End with Strong Institutional Interest